China Sky One Receives Seventh New Product Approval for 2009

China Sky One Medical (CSKI) was given approval by the SFDA to produce Diclofenac Sodium eye drops. The new product will be used to treat eye conditions including uveitis, keratitis and sclerotitis. Diclofenac Sodium eye drops are able to inhibit formation of unwanted blood vessels in the cornea and to reduce inflammation after eye operations, such as laser treatment, cataract surgery and intraocular lens operations. They can also help cure seasonal conjunctivitis and allergic conjunctivitis.

A generic product, Diclofenac Sodium eye drops are prescription medicines that are included in China medical insurance catalogues. China Sky One will launch the product in August 2009. It expects $500,000 in revenues in the first year of sales of Diclofenac Sodium eye drops.

In May, China Sky One received an SFDA go-ahead to begin clinical tests of Diclofenac Sodium suppositories as a treatment for rheumatoid arthritis and also for pain from surgery and fever.

So far in 2009, China Sky One Medical has been given production approvals for seven new drugs.

The company’s China operating subsidiaries are Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company. Most of the company’s products are OTC pharmaceutical products.

Disclosure: none.

Comments

[svygear:]

Check out the latest press release from ACCP.OB about their cancer drug partnerships in China and Korea:

Access Pharmaceuticals (ACCP.OB) provides an update on ProLindac(TM) Phase 2 Ovarian Cancer Trial : ProLindac Showing High DACH Platinum Activity; Drug Well Tolerated With No Signs of Acute Neurotoxicity

pitch.pe/13850

Jun 03 11:04 AM